BeiGene posts results for zanidatamab combo trial in HER2-positive breast, gastric cancers
BeiGene's Phase 1b/2 study of zanidatamab with chemotherapy, with or without tislelizumab, reports completed status and results after enrolling 71 participants.
This week's update centers on a single BeiGene-sponsored study now marked complete with results posted.
- Zanidatamab (ZW25), a bispecific antibody targeting HER2, was tested in combination with docetaxel and, in a separate patient group, with tislelizumab plus chemotherapy. The trial enrolled patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma.1 The study, "Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma," reached completed status, with primary completion dated 2023-12-071 and results first posted 2026-09-021. Enrollment reached 71 participants (actual)1. The primary outcomes tracked adverse events and serious adverse events, plus objective response rate defined using RECIST Version 1.1 criteria, assessed periodically over a maximum follow-up of 42 months.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.